Takeda Pharmaceutical annual revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Takeda Pharmaceutical Revenue Growth & History (TAK)
Takeda Pharmaceutical reported ¥4.51T in revenue for fiscal 2026, a decrease of 1.66% from the previous fiscal year.
View full Takeda Pharmaceutical company overviewTakeda Pharmaceutical annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | ¥4.51T | −¥75.83B | −1.66% |
| 2025 | 2025-03-31 | ¥4.58T | ¥317.79B | +7.45% |
| 2024 | 2024-03-31 | ¥4.26T | ¥236.28B | +5.87% |
| 2023 | 2023-03-31 | ¥4.03T | ¥458.47B | +12.85% |
| 2022 | 2022-03-31 | ¥3.57T | ¥371.19B | +11.61% |
| 2021 | 2021-03-31 | ¥3.20T | −¥93.38B | −2.84% |
| 2020 | 2020-03-31 | ¥3.29T | ¥1.19T | +56.93% |
| 2019 | 2019-03-31 | ¥2.10T | ¥326.69B | +18.45% |
| 2018 | 2018-03-31 | ¥1.77T | ¥38.48B | +2.22% |
| 2017 | 2017-03-31 | ¥1.73T | — | — |
Takeda Pharmaceutical quarterly revenue
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | ¥1.22T | ¥113.22B | +10.23% |
| Q4 2026 | 2026-03-31 | ¥1.09T | — | — |
| Q3 2026 | 2025-12-31 | ¥1.19T | — | — |
| Q2 2026 | 2025-09-30 | ¥1.11T | — | — |
| Q1 2026 | 2025-06-30 | ¥1.11T | — | — |
Takeda Pharmaceutical revenue growth trends
Over the last five reported fiscal years, revenue grew from ¥3.20T to ¥4.51T, a compound annual growth rate of 7.10%. Takeda Pharmaceutical's latest reported quarter, Q1 2027, generated ¥1.22T in revenue, an increase of 10.23% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Takeda Pharmaceutical source filings ↗